Samsung Bioepis Selects Two Companies for Seoul Biohub Open Innovation Program
Frazier Therapeutics and BioInsight Join Program
Support for TPD and AI-based Drug Development Technologies
Collaboration Opportunities in Joint Research and Technology Transfer
Samsung Bioepis announced on the 22nd that it has selected two participating companies for the '2026 Seoul Biohub-Samsung Bioepis Open Innovation Program,' which it operates in partnership with Seoul Biohub, and held an agreement ceremony.
Stakeholders are taking a commemorative photo at the 2026 Seoul Biohub-Samsung Bioepis Open Innovation Program Agreement Ceremony. Samsung Bioepis
View original imageThe selected companies are Frazier Therapeutics, which owns next-generation targeted protein degradation (TPD) platform technology, and BioInsight, which develops an AI-based chemoproteomics platform technology.
This program was established to promote collaboration between domestic biotech startups and global bio companies, as well as to increase the commercialization potential of next-generation bio technologies. Samsung Bioepis will provide the selected companies with support such as technology advancement, mentoring, and commercialization consulting. After the program ends, the company will consider further collaborations, including joint research, technology transfer, joint commercialization, and strategic investments, following a final evaluation.
Frazier Therapeutics is developing a next-generation TPD platform that removes disease-causing proteins by utilizing intracellular protein degradation systems. BioInsight possesses a chemoproteomics platform that utilizes mass spectrometry and artificial intelligence (AI) to analyze drug-protein interactions and discover new drug targets.
Kim Kyung-Ah, CEO of Samsung Bioepis, stated, "Through this program, we will discover next-generation bio technologies and expand our partnership base with promising biotech companies," and added, "We will also strive to contribute to the growth of the domestic bio ecosystem."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Previously, Samsung Bioepis also signed a memorandum of understanding (MOU) for open innovation collaboration with Atlatl Innovation Center, a Chinese biotech incubation institute, further expanding partnerships to secure next-generation technologies.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.